Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Investor's Business Daily on MSN6d
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?
Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...
Investor's Business Daily on MSN7d
Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook
Exact Sciences stock tumbled late Tuesday after the company cut its outlook and posted weaker-than-expected results.Shares of ...
Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Yahoo Finance5d
Exact Sciences’ forecast cut shocks analysts
Exact Sciences reported third-quarter results that fell short of ... a “shocking guidance update,” contributed to a 23% drop ...
Exact Sciences (NASDAQ:EXAS) Shares Gap Down on Disappointing Earnings
Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...
Exact Sciences Stock Falls After Cutting Outlook, Posting Lower-Than-Expected 3Q Results
Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.
Exact Sciences (NASDAQ:EXAS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price target boosted by stock analysts at Canaccord Genuity Group from ...
Exact Sciences price target lowered to $75 from $88 at BofA
BofA lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $88 and keeps a Buy rating on the shares after the company ...
Exact Sciences: Long-Term Growth Prospects Intact Despite Short-Term Challenges
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...